Researchers looked at how a specific treatment called DSM-TACE compares to standard treatments for patients with hepatocellular carcinoma, a type of liver cancer. This review looked at a small number of studies, including one clinical trial and five observational studies. The goal was to see if this newer method improved how tumors responded or helped patients live longer.
The results showed that DSM-TACE performed similarly to conventional treatments in terms of shrinking tumors. While there was a slight trend toward lower liver enzyme levels and a more favorable safety profile, these improvements were not statistically significant. This means the data did not clearly prove that the new method is safer or more effective than the current standard.
Because the data for safety was limited and not consistent across studies, it is hard to say for certain how the treatment compares in terms of side effects. This treatment is currently seen as an exploratory option that might be used as part of a personalized plan. More large, well-designed clinical trials are needed to confirm if this method offers any real advantages over current options.
